Received: from netlink.com.au (merlin.netlink.com.au [203.16.172.196])
	by csf.Colorado.EDU (8.9.1a/8.9.1/ITS-5.0/csf) with ESMTP id GAA18476
	for <ppn@csf.colorado.edu>; Wed, 11 Nov 1998 06:17:23 -0700 (MST)
Received: from netlink.com.au (h150.mel.netlink.com.au [203.62.225.150])
	by netlink.com.au (8.8.8/8.8.8) with ESMTP id AAA08621
	for <ppn@csf.colorado.edu>; Thu, 12 Nov 1998 00:21:59 +1100
Message-ID: <36498E1E.EA8071C2@netlink.com.au>
Date: Thu, 12 Nov 1998 00:16:14 +1100
From: rc&am <rcollins@netlink.com.au>
Reply-To: rcollins@netlink.com.au
MIME-Version: 1.0
To: PROGRESSIVE POPULATION NETWORK <ppn@csf.colorado.edu>
Subject: [Fwd: sterilisation]
Content-Type: multipart/mixed; boundary="------------8AABE1B03701847BFA7C6AB7"
This is a multi-part message in MIME format.
--------------8AABE1B03701847BFA7C6AB7
Content-Type: text/plain; charset=us-ascii
Content-Transfer-Encoding: 7bit



--------------8AABE1B03701847BFA7C6AB7
Content-Type: message/rfc822; name="nsmail6I.TMP"
Content-Transfer-Encoding: 7bit
Content-Disposition: inline; filename="nsmail6I.TMP"

Message-ID: <3648625C.713AA714@netlink.com.au>
Date: Wed, 11 Nov 1998 02:57:16 +1100
From: rc&am <rcollins@netlink.com.au>
Reply-To: rcollins@netlink.com.au
MIME-Version: 1.0
To: Ed Glaze III <eglaze@vsta.com>
Subject: Re: sterilisation
References: <01be0bfd$788d2520$516039cc@eglaze.vsta.com>
Content-Type: text/plain; charset=us-ascii
Content-Transfer-Encoding: 7bit

Mr glaze,

i will not take you up on all the dubious propositions resting behind your
seemingly concerned arguments.

i will however ask you one specific question re your comment below:

Ed Glaze III wrote:

> Pharmaceutical companies also
> need to test their procedures and in some cases they may be
> doing so in methods that take advance of the poor or others.

Namely: have you - or do you still - support the trials of quinacrine
sterilisation?

angela



--------------8AABE1B03701847BFA7C6AB7--